Lasa Supergenerics — 360° view

Lasa Supergenerics, a company in the Pharmaceuticals industry, reported revenue of ₹0.01 crore and a net loss of ₹1.84 crore for the September 2026 quarter.

Lasa Supergenerics (NSE: LASA-BE) closed at ₹4.01 on 16 Nov 2026. Its market capitalisation is ₹20 crore.

Share price
₹4.01 (16 Nov 2026)
Market cap
₹20 Cr (16 Nov 2026)
Revenue
₹0 Cr (September 2026 quarter)
Net profit
₹-2 Cr (September 2026 quarter)
ROCE
-18.2% (FY26)
ROE
-19.7% (FY26)
Book value
₹8.82 (FY26)
Dividend yield
0.00% (last 12 months to 16 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: LASA-BE

Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.